After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease
Summary
It’s the latest step in a fast-moving journey for the La Jolla, CA-based company, which raised about $65 million in an initial public offering in October just 19 months after its founding. Headed by former Amylin CEO Dan Bradbury, Equillium (NASDAQ: EQ ) has licensed the drug, itolizumab, which it calls EQ001, from Indian pharma giant Biocon Limited for development in the United States and Canada. The company plans to initiate a proof-of-concept trial for EQ001 as an LN treatment in the second half of this year, and says the data will inform future development of the drug in systemic lupus as well as a form of the disease that affects solely the skin. The compound is the only one to which Equillium has rights, although Bruce Steel, Equillium’s president and chief business officer, said in an interview with Xconomy earlier this year that the company is actively looking for additional programs to in-license. Jason Keyes, the company’s chief financial officer, worked with Bradbury at Amylin and held roles at other publicly traded businesses, as did Christine Zadelmayer, Equillium’s vice president of operations.
Classifications
AskAI Classifications
LabelsLinked Companies
